|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/23/10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/23/25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -1.95% | - | - | 572.55Cr | |
| -1.02% | -3.41% | +16.14% | +62.78% | 4.7TCr | |
| -1.80% | -6.33% | +37.87% | +114.34% | 3.99TCr | |
| -1.07% | -2.23% | +7.49% | +77.79% | 1.18TCr | |
| +0.51% | -1.61% | -12.25% | +10.01% | 1.16TCr | |
| +0.38% | +0.19% | +19.18% | +137.27% | 918.33Cr | |
| -0.40% | -5.88% | +34.57% | -17.80% | 719.96Cr | |
| -0.82% | -1.50% | +13.67% | +198.69% | 722.14Cr | |
| +0.16% | -2.11% | +24.78% | +33.33% | 732.08Cr | |
| +1.32% | +0.10% | -43.62% | +22.77% | 520.09Cr | |
| Average | -0.23% | -2.25% | +10.87% | +71.02% | 1.52TCr | |
| Weighted average by Cap. | -0.72% | -3.03% | +18.41% | +78.40% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
